A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Immuneering Corporation
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
Immuneering Corporation
Nimbus Therapeutics
Icahn School of Medicine at Mount Sinai
Mural Oncology, Inc
Acrotech Biopharma Inc.
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Celldex Therapeutics
Memorial Sloan Kettering Cancer Center